CBP/p300-IN-22
CBP/p300-IN-22 is a selective CBP/EP300-BRD inhibitor with an IC50 of 4 nM. CBP/p300-IN-22 is highly selective over BRD4 (1) . CBP/p300-IN-22 reduces TNF-α-induced cytokine expression and subsequent immune cell recruitment by inhibiting NF-κB signaling, and has anticancer activity. CBP/p300-IN-22 can be used for the research of rheumatoid arthritis (RA) and other TNF-α-mediated inflammatory conditions[1].
Product Specifications
UNSPSC
12352005
Target
Epigenetic Reader Domain; Histone Acetyltransferase; NF-κB
Related Pathways
Epigenetics; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Smiles
CC1=CC2=C(NC(C3=CC(C4=NN(C)C=C4)=CC(NC(C5=CC=CO5)=O)=C3)=O)C=CC=C2N=N1
Molecular Formula
C25H20N6O3
Molecular Weight
452.46
References & Citations
[1]Gosselé KA, et al. Selective CBP/EP300 Bromodomain Inhibitors: Novel Epigenetic Tools to Counter TNF-α-Driven Inflammation. JACS Au. 2025 Jun 5;5 (6) :2491-2499.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4; CBP/p300
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1610135-01 96 Strip Well
Bird Reticuloendotheliosis Virus antigen ELISA Kit
Sign In for Pricing
View Details MBS1610135-02 5x 96 Strip Well
Bird Reticuloendotheliosis Virus antigen ELISA Kit
Sign In for Pricing
View Details MBS1610135-03 10x 96 Strip Well
Bird Reticuloendotheliosis Virus antigen ELISA Kit
Sign In for Pricing
View Details